-
1
-
-
1842530296
-
Causes and prevalence of visual impairment among adults in the United States
-
DOI 10.1001/archopht.122.4.477
-
Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485. (Pubitemid 38456282)
-
(2004)
Archives of Ophthalmology
, vol.122
, Issue.4
, pp. 477-485
-
-
Congdon, N.1
-
2
-
-
0025776268
-
Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study
-
Macular Photocoagulation Study Group
-
Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1242-1257.
-
(1991)
Arch Ophthalmol
, vol.109
, pp. 1242-1257
-
-
-
3
-
-
0025837828
-
Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
-
Macular Photocoagulation Study Group
-
Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-1231.
-
(1991)
Arch Ophthalmol
, vol.109
, pp. 1220-1231
-
-
-
4
-
-
0025887896
-
Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial
-
Macular Photocoagulation Study Group
-
Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1232-1241.
-
(1991)
Arch Ophthalmol
, vol.109
, pp. 1232-1241
-
-
-
5
-
-
0342632445
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Oneyear results of 2 randomized clinical trials-TAP report 1
-
Treatment of age-related macular degeneration with photody- namic therapy (TAP) Study Group
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: oneyear results of 2 randomized clinical trials-TAP report 1. Treatment of age-related macular degeneration with photody- namic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329-1345.
-
(1999)
Arch Ophthalmol
, vol.117
, pp. 1329-1345
-
-
-
6
-
-
11144239923
-
Pegaptanib for neovascular age-related macular degeneration
-
VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
-
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
-
(2004)
N Engl J Med
, vol.351
, pp. 2805-2816
-
-
Gragoudas, E.S.1
Adamis, A.P.2
Cunningham Jr., E.T.3
Feinsod, M.4
Guyer, D.R.5
-
7
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
MARINA Study Group
-
Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
-
(2006)
N Engl J Med
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
-
8
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
ANCHOR Study Group
-
Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
-
(2006)
N Engl J Med
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
-
9
-
-
26844485888
-
The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data
-
Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687.
-
(2005)
Am J Ophthalmol
, vol.140
, pp. 679-687
-
-
Brown, G.C.1
Brown, M.M.2
Campanella, J.3
Beauchamp, G.R.4
-
10
-
-
44349110000
-
A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration
-
Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115:1039 -1045.e5.
-
(2008)
Ophthalmology
, vol.115
, pp. 1039-1045
-
-
Brown, M.M.1
Brown, G.C.2
Brown, H.C.3
Peet, J.4
-
11
-
-
36749011885
-
Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada
-
Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007; 29:2096-2106.
-
(2007)
Clin Ther
, vol.29
, pp. 2096-2106
-
-
Earnshaw, S.R.1
Moride, Y.2
Rochon, S.3
-
12
-
-
48949116261
-
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
-
Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008;6:12.
-
(2008)
Cost Eff Resour Alloc
, vol.6
, pp. 12
-
-
Hurley, S.F.1
Matthews, J.P.2
Guymer, R.H.3
-
13
-
-
47749151493
-
Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity
-
Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health 2007;11:563-574.
-
(2007)
Value Health
, vol.11
, pp. 563-574
-
-
Javitt, J.C.1
Zlateva, G.P.2
Earnshaw, S.R.3
-
14
-
-
0034759058
-
The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration
-
DOI 10.1016/S0161-6420(01)00764-3, PII S0161642001007643
-
Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059. (Pubitemid 33032778)
-
(2001)
Ophthalmology
, vol.108
, Issue.11
, pp. 2051-2059
-
-
Sharma, S.1
Brown, G.C.2
Brown, M.M.3
Hollands, H.4
Shah, G.K.5
-
15
-
-
34247358129
-
Relative cost of a line of vision in age-related macular degeneration
-
Smiddy WE. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology 2007;114:847-854.
-
(2007)
Ophthalmology
, vol.114
, pp. 847-854
-
-
Smiddy, W.E.1
-
17
-
-
18844394808
-
How to interpret a healthcare economic analysis
-
Brown MM, Brown GC. How to interpret a healthcare economic analysis. Curr Opin Ophthalmol 2005;16:191-194.
-
(2005)
Curr Opin Ophthalmol
, vol.16
, pp. 191-194
-
-
Brown, M.M.1
Brown, G.C.2
-
18
-
-
0037314160
-
National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10
-
Clemons TE, Chew EY, Bressler SB, McBee W; Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol 2003;121:211-217. (Pubitemid 36184034)
-
(2003)
Archives of Ophthalmology
, vol.121
, Issue.2
, pp. 211-217
-
-
Clemons, T.E.1
Chew, E.Y.2
Bressler, S.B.3
McBee, W.4
-
19
-
-
0003951293
-
-
American Academy of Ophthalmology. San Francisco: American Academy of Ophthalmology
-
American Academy of Ophthalmology. Preferred Practice Pattern. Age-Related Macular Degeneration. San Francisco: American Academy of Ophthalmology; 2001.
-
(2001)
Preferred Practice Pattern. Age-Related Macular Degeneration
-
-
-
20
-
-
16844375997
-
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial
-
Visudyne in Minimally Classic Choroidal Neovascularization Study Group
-
Azab M, Boyer DS, Bressler NM, et al; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448-457.
-
(2005)
Arch Ophthalmol
, vol.123
, pp. 448-457
-
-
Azab, M.1
Boyer, D.S.2
Bressler, N.M.3
-
21
-
-
0036145056
-
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2
-
Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133:168-169.
-
(2002)
Am J Ophthalmol
, vol.133
, pp. 168-169
-
-
Bressler, N.M.1
-
22
-
-
0036875646
-
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group
-
Bressler NM, Arnold J, Benchaboune M, et al; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002;120:1443-1454.
-
(2002)
Arch Ophthalmol
, vol.120
, pp. 1443-1454
-
-
Bressler, N.M.1
Arnold, J.2
Benchaboune, M.3
-
23
-
-
0036305925
-
Quality of life with visual acuity loss from diabetic retinopathy and agerelated macular degeneration
-
Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and agerelated macular degeneration. Arch Ophthalmol 2002;120:481-484.
-
(2002)
Arch Ophthalmol
, vol.120
, pp. 481-484
-
-
Brown, M.M.1
Brown, G.C.2
Sharma, S.3
Landy, J.4
Bakal, J.5
-
25
-
-
1842556553
-
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials-TAP and VIP report No. 3
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy Study Group
-
Arnold JJ, Blinder KJ, Bressler NM, et al; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report No. 3. Am J Ophthalmol 2004;137:683-696.
-
(2004)
Am J Ophthalmol
, vol.137
, pp. 683-696
-
-
Arnold, J.J.1
Blinder, K.J.2
Bressler, N.M.3
-
26
-
-
33646948521
-
Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials
-
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group
-
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.e6.
-
(2006)
Ophthalmology
, vol.113
, pp. 992-1001
-
-
D'Amico, D.J.1
Masonson, H.N.2
Patel, M.3
-
27
-
-
0024523990
-
Methodology for measuring healthstate preferences-I: Measurement strategies
-
Froberg DG, Kane RL. Methodology for measuring healthstate preferences-I: measurement strategies. J Clin Epidemiol 1989;42:345-354.
-
(1989)
J Clin Epidemiol
, vol.42
, pp. 345-354
-
-
Froberg, D.G.1
Kane, R.L.2
-
28
-
-
0024354921
-
Methodology for measuring healthstate preferences-II: Scaling methods
-
Froberg DG, Kane RL. Methodology for measuring healthstate preferences-II: scaling methods. J Clin Epidemiol 1989; 42:459-471.
-
(1989)
J Clin Epidemiol
, vol.42
, pp. 459-471
-
-
Froberg, D.G.1
Kane, R.L.2
-
29
-
-
0024375537
-
Methodology for measuring healthstate preferences-IV: Progress and a research agenda
-
Froberg DG, Kane RL. Methodology for measuring healthstate preferences-IV: progress and a research agenda. J Clin Epidemiol 1989;42:675-685.
-
(1989)
J Clin Epidemiol
, vol.42
, pp. 675-685
-
-
Froberg, D.G.1
Kane, R.L.2
-
30
-
-
0024413278
-
Methodology for measuring healthstate preferences-III: Population and context effects
-
Froberg DG, Kane RL. Methodology for measuring healthstate preferences-III: population and context effects. J Clin Epidemiol 1989;42:585-592.
-
(1989)
J Clin Epidemiol
, vol.42
, pp. 585-592
-
-
Froberg, D.G.1
Kane, R.L.2
-
31
-
-
6344225683
-
Value-based medicine: A new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions
-
Busbee BG, Brown GC, Brown MM. Value-based medicine: a new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions. Int Ophthalmol Clin 2004;44:155-172.
-
(2004)
Int Ophthalmol Clin
, vol.44
, pp. 155-172
-
-
Busbee, B.G.1
Brown, G.C.2
Brown, M.M.3
-
32
-
-
0035124965
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-Tap report 2
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group
-
Bressler NM; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-Tap report 2. Arch Ophthalmol 2001;119:198-207.
-
(2001)
Arch Ophthalmol
, vol.119
, pp. 198-207
-
-
Bressler, N.M.1
-
33
-
-
57949094834
-
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
-
ANCHOR Study Group
-
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57- 65.e5.
-
(2009)
Ophthalmology
, vol.116
, pp. 57-65
-
-
Brown, D.M.1
Michels, M.2
Kaiser, P.K.3
Heier, J.S.4
Sy, J.P.5
Ianchulev, T.6
-
34
-
-
38349172455
-
Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
-
Regillo C, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 239-248
-
-
Regillo, C.1
Brown, D.M.2
Abraham, P.3
-
35
-
-
21744452454
-
Drug pricing for a novel treatment for wet macular degeneration: Using incremental cost-effectiveness ratios to ensure societal value
-
Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40:369-377.
-
(2005)
Can J Ophthalmol
, vol.40
, pp. 369-377
-
-
Sharma, S.1
Bakal, J.2
Sharma, S.M.3
Covert, D.4
Shah, G.K.5
-
36
-
-
34548355065
-
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
-
DRCRnet and the SCORE Study Groups
-
Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144:454-456.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 454-456
-
-
Bhavsar, A.R.1
Ip, M.S.2
Glassman, A.R.3
|